Physician profile
Christopher J Wright
NPI 1902983026
$9,116.59
in general payments reported to CMS, 2019-2025
43 companies · $2,793 in 2025
The $2,793 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $243 · 2021: $257 · 2022: $589 · 2023: $1,500 · 2024: $3,315 · 2025: $2,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,526 · Education: $81.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,525.78 |
| Education | $81.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,113.37 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Novartis Pharmaceuticals Corporation | $1,060.72 | 2022-2025 | |
| Mdd US Operations, LLC | $659.39 | 2024-2025 | Gocovri, Apokyn |
| Amgen INC. | $603.63 | 2019-2025 | Uplizna, Aimovig |
| Amneal Pharmaceuticals LLC | $437.63 | 2023-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Lilly USA, LLC | $424.20 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $286.00 | 2024-2025 | |
| Ucb, INC. | $233.63 | 2023-2025 | Rystiggo, Zilbrysq |
| Csl Behring | $217.15 | 2019-2025 | Hizentra |
| Pfizer INC. | $216.69 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $184.69 | 2019-2025 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $151.69 | 2020-2024 | Austedo Xr, Ajovy |
| Springworks Therapeutics, INC. | $124.92 | 2025 | Gomekli |
| Lundbeck LLC | $119.51 | 2023-2025 | Vyepti |
| Genentech USA, INC. | $111.28 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $103.24 | 2023-2025 | Valtoco |
| Livanova USA, INC. | $90.83 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Argenx US, INC. | $87.70 | 2024-2025 | Vyvgart Hytrulo |
| Celgene Corporation | $77.25 | 2024 | Zeposia |
| Supernus Pharmaceuticals, INC. | $75.73 | 2019-2021 | |
| Emd Serono, INC. | $69.67 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $68.83 | 2024-2025 | Dysport |
| Biohaven Pharmaceuticals, INC. | $59.92 | 2021 | |
| Biogen, INC. | $53.36 | 2020-2025 | Vumerity |
| Tg Therapeutics, INC. | $44.83 | 2025 | |
| Merz Pharmaceuticals, LLC | $43.34 | 2025 | Xeomin, Inbrija, Ampyra |
| Takeda Pharmaceuticals U.S.A., INC. | $39.36 | 2025 | Hyqvia |
| Allergan, INC. | $38.77 | 2019-2020 | |
| Kedrion Biopharma, INC. | $35.16 | 2025 | Koate, Albuked, Kedrab |
| Genzyme Corporation | $32.70 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $23.58 | 2023 | Aptiom |
| Merz North America, INC. | $23.42 | 2020 | |
| Alnylam Pharmaceuticals INC. | $22.69 | 2023 | Onpattro |
| Endo USA, INC. | $21.98 | 2025 | Xiaflex |
| Sunovion Pharmaceuticals INC. | $21.79 | 2021 | |
| Cycle Pharmaceuticals INC | $20.54 | 2025 | Tascenso Odt, Bafiertam |
| Neurocrine Biosciences, INC. | $19.08 | 2024 | Ingrezza |
| Tanabe Pharma America, INC. | $18.93 | 2024 | |
| Vertical Pharmaceuticals, LLC | $17.57 | 2020 | |
| Grifols USA, LLC | $17.02 | 2025 | Gamunex-C |
| Acadia Pharmaceuticals INC | $16.43 | 2023 | Nuplazid |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.21 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.